Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 4Head & Neck 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1

Conditions

Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 8Nasopharyngeal Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Osteosarcoma 2Optic Nerve Glioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Melanoma 2Familial ependymoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Astrocytoma 2Wilms Tumor 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 30Nivolumab 10Cyclophosphamide 9fludarabine 7atezolizumab 7aldesleukin 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Carboplatin 5Biopsy 5cemiplimab 4Trastuzumab 4Interleukin-2 4Docetaxel 4Cisplatin 4spartalizumab 3durvalumab 3Specimen Handling 3Polymerase Chain Reaction 3Gene Expression Profiling 3Fulvestrant 3Fluorouracil 3tisotumab vedotin 2tislelizumab 2palbociclib 2fludarabine phosphate 2entinostat 2avelumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Oxaliplatin × Head & Neck × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡